leisure time -WSS

leisure time

author：knowledge 2025-09-29 15:24:39 - browse：2

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： STAT Readout Newsletter: Today in biotech, life science news

entertainment

WSS

Listen: Biogen's potential pivot, & Illumina's next chapter

Crinetics acromegaly drug succeeds in late

Snackable artificial intelligence, expert AI, and the pharma industry

A revolution in caring for preterm infants

Medicare to cover more brain scans related to Alzheimer’s drugs

European regulators consider appeal over Amylyx ALS drug

knowledge

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

knowledge

Apple is now the first public company to be valued at $3 trillion

'Make People Better': The CRISPR babies story you probably don't know

Affirmative action in medical school literally saved lives

How to fix cancer clinical trials' diversity problem

Peter Hotez and the public health issue of online harassment

A new House health package & hospitals’ new site

BioMarin wins approval for gene therapy to treat hemophilia A

Trump surgeon general acknowledges mistakes during Covid

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Humana CEO Bruce Broussard to step down in 2024

entertainment

What's changing in Medicare's open enrollment this year?

Cancer cells are shown to suck energy source from immune cells

Humana CEO Bruce Broussard to step down in 2024

Takeaways from AdvaMed, the largest medical devices conference

A revolution in caring for preterm infants

Medicaid rebukes states for mistakenly disenrolling children

knowledge

focus

entertainment

hotspot